A pivotal Phase 3 study investigating melflufen (melphalan flufenamide) plus dexamethasone in people with relapsed or refractory multiple myeloma is fully enrolled, Oncopeptides, the treatment’s developer, announced. The OCEAN trial (NCT03151811) recruited 450 patients across more than 100 clinical sites worldwide, and top-line results are expected later this year. “I am very pleased to announce that we managed to complete enrollment in the OCEAN study despite the strenuous situation that our research and healthcare providers currently are…
You must be logged in to read/download the full post.
The post Phase 3 Trial of Melflufen Combo in Advanced Multiple Myeloma Fully Enrolled appeared first on BioNewsFeeds.